KRAS-targeted therapies in advanced solid cancers: drug the undruggable?

Pharmacogenomics. 2021 Jul;22(10):587-590. doi: 10.2217/pgs-2021-0045. Epub 2021 Jun 21.

Authors

Khalil Saleh¹, Manal Kordahi², Tony Felefly³, Hampig Raphael Kourie⁴, Nadine Khalife⁵

Affiliations

¹ Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, 94800, France.
² Department of Pathology, National Institute of Pathology, Baabda, 1003, Lebanon.
³ Department of Radiation Oncology, Hotel-Dieu de France University Hospital, School of Medicine, Saint-Joseph University, Beirut, 1100, Lebanon.
⁴ Department of Hematology-Oncology, Faculty of Medicine, Saint-Joseph University, Beirut, 1100, Lebanon.
⁵ Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, France.

PMID: 34148378
DOI: 10.2217/pgs-2021-0045

No abstract available

Keywords: KRASG12C mutations; RAS; adagrasib; colorectal cancer; non-small-cell lung cancer; sotorasib.

Publication types

Editorial

MeSH terms

Acetonitriles / administration & dosage
Antineoplastic Agents / administration & dosage*
Drug Delivery Systems / methods*
Drug Delivery Systems / trends
Drug Resistance, Neoplasm / drug effects
Drug Resistance, Neoplasm / physiology
Humans
Immune Checkpoint Inhibitors / administration & dosage*
Neoplasms / drug therapy*
Neoplasms / genetics
Neoplasms / metabolism
Piperazines / administration & dosage
Proto-Oncogene Proteins p21(ras) / antagonists & inhibitors*
Proto-Oncogene Proteins p21(ras) / genetics
Proto-Oncogene Proteins p21(ras) / metabolism
Pyridines / administration & dosage
Pyrimidines / administration & dosage

Substances

Acetonitriles
Antineoplastic Agents
Immune Checkpoint Inhibitors
KRAS protein, human
Piperazines
Pyridines
Pyrimidines
sotorasib
adagrasib
Proto-Oncogene Proteins p21(ras)